Nicorandil improves diabetes and rat islet β-cell damage induced by streptozotocin in vivo and in vitro

European Journal of Endocrinology

Volumn 151, Issue 2, 2004, Pages 277-285

  Kasono, K ^a   Yasu, T ^a   Kakehashi, A ^a   Kinoshita, N ^a   Tamemoto, H ^a   Namai, K ^a   Ohno, R ^a   Ueba, H ^a   Kuroki, M ^a   Ishikawa, S ^a   Kawakami, M ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; GLUCOSE; INSULIN; NICORANDIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE DONOR; POTASSIUM CHANNEL STIMULATING AGENT; REACTIVE OXYGEN METABOLITE; SCAVENGER; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULINOMA; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT STRAIN; STREPTOZOCIN DIABETES; TISSUE CULTURE; TISSUE INJURY; TUMOR CELL; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; FREE RADICAL SCAVENGERS; GLUCAGON; INSULIN; ISLETS OF LANGERHANS; MALE; NICORANDIL; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, INBRED BN; REACTIVE OXYGEN SPECIES; SUPEROXIDES; VASODILATOR AGENTS;

EID: 4444339049     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510277     Document Type: Article

References (39)

1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. New England Journal of Medicine 1986 314 1360-1368.
2. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Reviews 1994 15 516-542.
3. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996 39 1005-1029.
4. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S & Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001 50 (Suppl 1) S154-S159.
5. Sakurai T & Tsuchiya S. Superoxide production from nonenzymatically glycated protein. FEBS Letters 1988 236 406-410.
6. Hunt JV, Smith CC & Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990 39 1420-1424.
7. Myint T, Hoshi S, Ookawara T, Miyazawa N, Suzuki K & Taniguchi N. Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochimica et Biophysica Acta 1995 1272 73-79.
8. Kaneto H, Fujii J, Myint T, Miyazawa N, Islam KN, Kawasaki Y et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochemical Journal 1996 320 855-863.
9. Tajiri Y, Moller C & Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology 1997 138 273-280.
10. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H et al. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999 48 927-932.
11. Kaneto H, Kajimoto Y, Miyazawa J, Matsuoka T, Fujitani Y, Umayahara Y et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999 48 2398-2406.
12. Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J et al. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. Journal of Experimental Medicine 1998 188 1445-1451.
13. Xu B, Moritz JT & Epstein PN. Overexpression of catalase provides partial protection to transgenic mouse beta cells. Free Radical Biology and Medicine 1999 27 830-837.
14. Chen H, Carlson EC, Pellet L, Moritz JT & Epstein PN. Overexpression of metallothionein in pancreatic β-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 2001 50 2040-2046.
15. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. American Journal of Cardiology 1989 63 18J-24J.
16. Krumenacker M & Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. Journal of Cardiovascular Pharmacology 1992 20 (Suppl 3) S93-S102.
17. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002 359 1269-1275.
18. Pieper GM & Gross GJ. Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovascular Drugs and Therapy 1992 6 225-232.
19. Mano T, Shinohara R, Nagasaka A, Nakagawa H, Uchimura K, Hayashi R et al. Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin-induced diabetic rats. Metabolism 2000 49 427-431.
20. Okamoto H. Molecular basis of experimental diabetes: degeneration, oncogenesis and regeneration of pancreatic β-cells of islet of Langerhans. Bioassays 1985 2 15-21.
21. 14C]-streptozotocin with special reference to the pancreatic islets. Acta Endocrinologica 1969 89 339-347.
22. Schnedl WJ, Ferber S, Johnson JH & Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994 43 1326-1333.
23. Elsner M, Guldbakke B, Tiedge M, Munday R & Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 2000 43 1528-1533.
24. Schein PS, Cooney DA, McMenamin MG & Anderson T. Streptozotocin diabetes - further studies on the mechanism of depression of nicotinamide adenine dinucleotide concentrations in mouse pancreatic islets and liver. Biochemical Pharmacology 1973 22 2625-2631.
25. Kwon NS, Lee SH, Choi CS, Kho T & Lee HS. Nitric oxide generation from streptozotocin. FASEB Journal 1994 8 529-533.
26. Corbett JA, Lancaster JR Jr, Sweetland MA & McDaniel ML. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion. Journal of Biological Chemistry 1991 266 21351-21354.
27. Gandy SE, Buse MG & Crouch RK. Protective role of superoxide dismutase against diabetogenic drugs. Journal of Clinical Investigation 1982 70 650-658.
28. Ohkuwa T, Sato Y & Naoi M. Hydroxyl radical formation in diabetic rats induced by streptozotocin. Life Sciences 1995 56 1789-1798.
29. Yasu T, Ikeda N, Ishizuka N, Matsuda E, Kawakami M, Kuroki M et al. Nicorandil and leukocyte activation. Journal of Cardiovascular Pharmacology 2002 40 684-692.
30. Kinoshita N, Kakehashi A, Inoda S, Itou Y, Kuroki M, Yasu T et al. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 2002 45 735-739.
31. Kullin M, Li Z, Hansen JB, Bjork E, Sandler S & Karlsson FA. K(ATP) channel openers protect rat islets against the toxic effect of streptozotocin. Diabetes 2000 49 1131-1136.
32. Rasmussen SB, Sorensen TS, Hansen JB, Mandrup-Poulsen T, Hornum L & Markholst H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Hormone and Metabolic Research 2000 32 294-300.
33. Lebrun P, Antoine MH & Herchuelz A. K + channel openers and insulin release. Life Sciences 1992 51 795-806.
34. Garrino MG, Plant TD & Henquin JC. Effects of putative activators of K+channels in mouse pancreatic beta-cells. British Journal of Pharmacology 1989 98 957-965.
35. Dunne MJ. Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. British Journal of Pharmacology 1990 99 487-492.
36. Grankvist K, Marklund SL & Taljedal IB. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochemical Journal 1981 199 393-398.
37. Tiedge M, Lortz S, Drinkgern J & Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997 46 1733-1742.
38. Lenzen S, Drinkgern J & Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radical Biology and Medicine 1996 20 463-466.
39. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. PNAS 1999 96 3059-3064.